Global Polyglycol Laxatives Market

Polyglycol Laxatives Comprehensive Study by Type (Polyglycol 3350, Polyglycol 4000), Application (Chronic Constipation, Irritable Bowel Syndrome, Others), End Users (Adult, Children), Distribution Channel (Hospitals and Clinics, Pharmacies, Others) Players and Region - Global Market Outlook to 2027

Polyglycol Laxatives Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Polyglycol Laxatives Market Scope?
Laxatives, laxatives, or aperitifs are substances that loosen stool and increase bowel movements. They are used to treat and prevent constipation. Laxatives vary in terms of how they work and the possible side effects. Certain stimulants, lubricants, and saline laxatives are used to evacuate the colon for rectal and bowel exams and may be supplemented with enemas in certain circumstances. High enough doses of laxatives can cause diarrhea. Some laxatives combine more than one active ingredient. Laxatives can be administered orally or rectally. Although patients with eating disorders such as anorexia nervosa and bulimia nervosa often misuse laxatives to lose weight, laxatives speed up the passage of feces across the large intestine, which occurs after the small intestine has finished absorbing nutrients. Laxative abuse studies have therefore shown that the effects on body weight are primarily due to temporary losses of body water rather than energy (calorie) losses. Doctors caution against chronic laxative use as they fear that chronic use could cause colon tissue to wear out over time, making it impossible to expel feces due to long-term overstimulation. A common finding in people who have used laxatives is a brown pigment known as melanosis coli deposited in the intestinal tissue.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledBayer AG (Germany), Boehringer Ingelheim Pharmaceutical (Germany), GSK (United Kingdom), Purdue Pharma (United States), Sucampo Pharmaceuticals (United States), Norgine Limited (United Kingdom), Cipla (India), Perrigo Company (Ireland) and Ipsen (France)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Polyglycol Laxatives market study is being classified by Type (Polyglycol 3350 and Polyglycol 4000), by Application (Chronic Constipation, Irritable Bowel Syndrome and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Polyglycol Laxatives market throughout the predicted period.

Bayer AG (Germany), Boehringer Ingelheim Pharmaceutical (Germany), GSK (United Kingdom), Purdue Pharma (United States), Sucampo Pharmaceuticals (United States), Norgine Limited (United Kingdom), Cipla (India), Perrigo Company (Ireland) and Ipsen (France) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Polyglycol Laxatives market by Type, Application and Region.

On the basis of geography, the market of Polyglycol Laxatives has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


The federal Food and Drug Administration (FDA) regulates healthcare professionals that the ultrasound contrast agents Definity, Definity RT, and Lumason contain polyethylene glycol (PEG) and should not be administered to patients with known or suspected allergies to PEG. Healthcare professionals should clinically assess patients to confirm they do not have a known or suspected allergy to PEG before administering Definity, Definity RT, and Humason.

Influencing Market Trend
  • Easily Availability of OTC Drugs
  • Unhealthy Eating Habits among Public
  • The Higher Prevalence of Constipation in the Geriatric Population

Market Drivers
  • Growth of Geriatric Population
  • Increasing Sedentary Lifestyle
  • Lack of Exercise
  • Rising Prevalence of Constipation Worldwide

Opportunities
  • The Growing Research and Development Activities
  • Surging Levels of Investment in Healthcare Infrastructure

Restraints
  • Fear of Side Effects

Challenges
  • The Presence of Alternative Medications


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Polyglycol Laxatives, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Polyglycol 3350
  • Polyglycol 4000
By Application
  • Chronic Constipation
  • Irritable Bowel Syndrome
  • Others
By End Users
  • Adult
  • Children

By Distribution Channel
  • Hospitals and Clinics
  • Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth of Geriatric Population
      • 3.2.2. Increasing Sedentary Lifestyle
      • 3.2.3. Lack of Exercise
      • 3.2.4. Rising Prevalence of Constipation Worldwide
    • 3.3. Market Challenges
      • 3.3.1. The Presence of Alternative Medications
    • 3.4. Market Trends
      • 3.4.1. Easily Availability of OTC Drugs
      • 3.4.2. Unhealthy Eating Habits among Public
      • 3.4.3. The Higher Prevalence of Constipation in the Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Polyglycol Laxatives, by Type, Application, End Users, Distribution Channel and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Polyglycol Laxatives (Value)
      • 5.2.1. Global Polyglycol Laxatives by: Type (Value)
        • 5.2.1.1. Polyglycol 3350
        • 5.2.1.2. Polyglycol 4000
      • 5.2.2. Global Polyglycol Laxatives by: Application (Value)
        • 5.2.2.1. Chronic Constipation
        • 5.2.2.2. Irritable Bowel Syndrome
        • 5.2.2.3. Others
      • 5.2.3. Global Polyglycol Laxatives by: End Users (Value)
        • 5.2.3.1. Adult
        • 5.2.3.2. Children
      • 5.2.4. Global Polyglycol Laxatives by: Distribution Channel (Value)
        • 5.2.4.1. Hospitals and Clinics
        • 5.2.4.2. Pharmacies
        • 5.2.4.3. Others
      • 5.2.5. Global Polyglycol Laxatives Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Polyglycol Laxatives (Price)
      • 5.3.1. Global Polyglycol Laxatives by: Type (Price)
  • 6. Polyglycol Laxatives: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim Pharmaceutical (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GSK (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Purdue Pharma (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sucampo Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Norgine Limited (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Perrigo Company (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ipsen (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Polyglycol Laxatives Sale, by Type, Application, End Users, Distribution Channel and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Polyglycol Laxatives (Value)
      • 7.2.1. Global Polyglycol Laxatives by: Type (Value)
        • 7.2.1.1. Polyglycol 3350
        • 7.2.1.2. Polyglycol 4000
      • 7.2.2. Global Polyglycol Laxatives by: Application (Value)
        • 7.2.2.1. Chronic Constipation
        • 7.2.2.2. Irritable Bowel Syndrome
        • 7.2.2.3. Others
      • 7.2.3. Global Polyglycol Laxatives by: End Users (Value)
        • 7.2.3.1. Adult
        • 7.2.3.2. Children
      • 7.2.4. Global Polyglycol Laxatives by: Distribution Channel (Value)
        • 7.2.4.1. Hospitals and Clinics
        • 7.2.4.2. Pharmacies
        • 7.2.4.3. Others
      • 7.2.5. Global Polyglycol Laxatives Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Polyglycol Laxatives (Price)
      • 7.3.1. Global Polyglycol Laxatives by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Polyglycol Laxatives: by Type(USD Million)
  • Table 2. Polyglycol Laxatives Polyglycol 3350 , by Region USD Million (2016-2021)
  • Table 3. Polyglycol Laxatives Polyglycol 4000 , by Region USD Million (2016-2021)
  • Table 4. Polyglycol Laxatives: by Application(USD Million)
  • Table 5. Polyglycol Laxatives Chronic Constipation , by Region USD Million (2016-2021)
  • Table 6. Polyglycol Laxatives Irritable Bowel Syndrome , by Region USD Million (2016-2021)
  • Table 7. Polyglycol Laxatives Others , by Region USD Million (2016-2021)
  • Table 8. Polyglycol Laxatives: by End Users(USD Million)
  • Table 9. Polyglycol Laxatives Adult , by Region USD Million (2016-2021)
  • Table 10. Polyglycol Laxatives Children , by Region USD Million (2016-2021)
  • Table 11. Polyglycol Laxatives: by Distribution Channel(USD Million)
  • Table 12. Polyglycol Laxatives Hospitals and Clinics , by Region USD Million (2016-2021)
  • Table 13. Polyglycol Laxatives Pharmacies , by Region USD Million (2016-2021)
  • Table 14. Polyglycol Laxatives Others , by Region USD Million (2016-2021)
  • Table 15. South America Polyglycol Laxatives, by Country USD Million (2016-2021)
  • Table 16. South America Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 17. South America Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 18. South America Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 19. South America Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 20. Brazil Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 21. Brazil Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 22. Brazil Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 23. Brazil Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 24. Argentina Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 25. Argentina Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 26. Argentina Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 27. Argentina Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 28. Rest of South America Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 29. Rest of South America Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 30. Rest of South America Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 31. Rest of South America Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 32. Asia Pacific Polyglycol Laxatives, by Country USD Million (2016-2021)
  • Table 33. Asia Pacific Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 34. Asia Pacific Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 35. Asia Pacific Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 36. Asia Pacific Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 37. China Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 38. China Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 39. China Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 40. China Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 41. Japan Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 42. Japan Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 43. Japan Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 44. Japan Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 45. India Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 46. India Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 47. India Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 48. India Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 49. South Korea Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 50. South Korea Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 51. South Korea Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 52. South Korea Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 53. Taiwan Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 54. Taiwan Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 55. Taiwan Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 56. Taiwan Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 57. Australia Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 58. Australia Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 59. Australia Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 60. Australia Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 65. Europe Polyglycol Laxatives, by Country USD Million (2016-2021)
  • Table 66. Europe Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 67. Europe Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 68. Europe Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 69. Europe Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 70. Germany Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 71. Germany Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 72. Germany Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 73. Germany Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 74. France Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 75. France Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 76. France Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 77. France Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 78. Italy Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 79. Italy Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 80. Italy Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 81. Italy Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 82. United Kingdom Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 83. United Kingdom Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 84. United Kingdom Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 85. United Kingdom Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 86. Netherlands Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 87. Netherlands Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 88. Netherlands Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 89. Netherlands Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 90. Rest of Europe Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 91. Rest of Europe Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 92. Rest of Europe Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 93. Rest of Europe Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 94. MEA Polyglycol Laxatives, by Country USD Million (2016-2021)
  • Table 95. MEA Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 96. MEA Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 97. MEA Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 98. MEA Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 99. Middle East Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 100. Middle East Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 101. Middle East Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 102. Middle East Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 103. Africa Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 104. Africa Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 105. Africa Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 106. Africa Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 107. North America Polyglycol Laxatives, by Country USD Million (2016-2021)
  • Table 108. North America Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 109. North America Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 110. North America Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 111. North America Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 112. United States Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 113. United States Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 114. United States Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 115. United States Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 116. Canada Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 117. Canada Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 118. Canada Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 119. Canada Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 120. Mexico Polyglycol Laxatives, by Type USD Million (2016-2021)
  • Table 121. Mexico Polyglycol Laxatives, by Application USD Million (2016-2021)
  • Table 122. Mexico Polyglycol Laxatives, by End Users USD Million (2016-2021)
  • Table 123. Mexico Polyglycol Laxatives, by Distribution Channel USD Million (2016-2021)
  • Table 124. Polyglycol Laxatives: by Type(USD/Units)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Polyglycol Laxatives: by Type(USD Million)
  • Table 135. Polyglycol Laxatives Polyglycol 3350 , by Region USD Million (2022-2027)
  • Table 136. Polyglycol Laxatives Polyglycol 4000 , by Region USD Million (2022-2027)
  • Table 137. Polyglycol Laxatives: by Application(USD Million)
  • Table 138. Polyglycol Laxatives Chronic Constipation , by Region USD Million (2022-2027)
  • Table 139. Polyglycol Laxatives Irritable Bowel Syndrome , by Region USD Million (2022-2027)
  • Table 140. Polyglycol Laxatives Others , by Region USD Million (2022-2027)
  • Table 141. Polyglycol Laxatives: by End Users(USD Million)
  • Table 142. Polyglycol Laxatives Adult , by Region USD Million (2022-2027)
  • Table 143. Polyglycol Laxatives Children , by Region USD Million (2022-2027)
  • Table 144. Polyglycol Laxatives: by Distribution Channel(USD Million)
  • Table 145. Polyglycol Laxatives Hospitals and Clinics , by Region USD Million (2022-2027)
  • Table 146. Polyglycol Laxatives Pharmacies , by Region USD Million (2022-2027)
  • Table 147. Polyglycol Laxatives Others , by Region USD Million (2022-2027)
  • Table 148. South America Polyglycol Laxatives, by Country USD Million (2022-2027)
  • Table 149. South America Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 150. South America Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 151. South America Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 152. South America Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 153. Brazil Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 154. Brazil Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 155. Brazil Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 156. Brazil Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 157. Argentina Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 158. Argentina Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 159. Argentina Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 160. Argentina Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 161. Rest of South America Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 162. Rest of South America Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 163. Rest of South America Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 164. Rest of South America Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 165. Asia Pacific Polyglycol Laxatives, by Country USD Million (2022-2027)
  • Table 166. Asia Pacific Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 167. Asia Pacific Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 168. Asia Pacific Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 169. Asia Pacific Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 170. China Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 171. China Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 172. China Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 173. China Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 174. Japan Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 175. Japan Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 176. Japan Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 177. Japan Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 178. India Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 179. India Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 180. India Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 181. India Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 182. South Korea Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 183. South Korea Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 184. South Korea Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 185. South Korea Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 186. Taiwan Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 187. Taiwan Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 188. Taiwan Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 189. Taiwan Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 190. Australia Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 191. Australia Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 192. Australia Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 193. Australia Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 194. Rest of Asia-Pacific Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 195. Rest of Asia-Pacific Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 198. Europe Polyglycol Laxatives, by Country USD Million (2022-2027)
  • Table 199. Europe Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 200. Europe Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 201. Europe Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 202. Europe Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 203. Germany Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 204. Germany Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 205. Germany Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 206. Germany Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 207. France Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 208. France Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 209. France Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 210. France Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 211. Italy Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 212. Italy Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 213. Italy Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 214. Italy Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 215. United Kingdom Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 216. United Kingdom Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 217. United Kingdom Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 218. United Kingdom Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 219. Netherlands Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 220. Netherlands Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 221. Netherlands Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 222. Netherlands Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 223. Rest of Europe Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 224. Rest of Europe Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 225. Rest of Europe Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 226. Rest of Europe Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 227. MEA Polyglycol Laxatives, by Country USD Million (2022-2027)
  • Table 228. MEA Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 229. MEA Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 230. MEA Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 231. MEA Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 232. Middle East Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 233. Middle East Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 234. Middle East Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 235. Middle East Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 236. Africa Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 237. Africa Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 238. Africa Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 239. Africa Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 240. North America Polyglycol Laxatives, by Country USD Million (2022-2027)
  • Table 241. North America Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 242. North America Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 243. North America Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 244. North America Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 245. United States Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 246. United States Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 247. United States Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 248. United States Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 249. Canada Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 250. Canada Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 251. Canada Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 252. Canada Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 253. Mexico Polyglycol Laxatives, by Type USD Million (2022-2027)
  • Table 254. Mexico Polyglycol Laxatives, by Application USD Million (2022-2027)
  • Table 255. Mexico Polyglycol Laxatives, by End Users USD Million (2022-2027)
  • Table 256. Mexico Polyglycol Laxatives, by Distribution Channel USD Million (2022-2027)
  • Table 257. Polyglycol Laxatives: by Type(USD/Units)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Polyglycol Laxatives: by Type USD Million (2016-2021)
  • Figure 5. Global Polyglycol Laxatives: by Application USD Million (2016-2021)
  • Figure 6. Global Polyglycol Laxatives: by End Users USD Million (2016-2021)
  • Figure 7. Global Polyglycol Laxatives: by Distribution Channel USD Million (2016-2021)
  • Figure 8. South America Polyglycol Laxatives Share (%), by Country
  • Figure 9. Asia Pacific Polyglycol Laxatives Share (%), by Country
  • Figure 10. Europe Polyglycol Laxatives Share (%), by Country
  • Figure 11. MEA Polyglycol Laxatives Share (%), by Country
  • Figure 12. North America Polyglycol Laxatives Share (%), by Country
  • Figure 13. Global Polyglycol Laxatives: by Type USD/Units (2016-2021)
  • Figure 14. Global Polyglycol Laxatives share by Players 2021 (%)
  • Figure 15. Global Polyglycol Laxatives share by Players (Top 3) 2021(%)
  • Figure 16. Global Polyglycol Laxatives share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 20. Boehringer Ingelheim Pharmaceutical (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Boehringer Ingelheim Pharmaceutical (Germany) Revenue: by Geography 2021
  • Figure 22. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GSK (United Kingdom) Revenue: by Geography 2021
  • Figure 24. Purdue Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 25. Purdue Pharma (United States) Revenue: by Geography 2021
  • Figure 26. Sucampo Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Sucampo Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 28. Norgine Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Norgine Limited (United Kingdom) Revenue: by Geography 2021
  • Figure 30. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 31. Cipla (India) Revenue: by Geography 2021
  • Figure 32. Perrigo Company (Ireland) Revenue, Net Income and Gross profit
  • Figure 33. Perrigo Company (Ireland) Revenue: by Geography 2021
  • Figure 34. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 35. Ipsen (France) Revenue: by Geography 2021
  • Figure 36. Global Polyglycol Laxatives: by Type USD Million (2022-2027)
  • Figure 37. Global Polyglycol Laxatives: by Application USD Million (2022-2027)
  • Figure 38. Global Polyglycol Laxatives: by End Users USD Million (2022-2027)
  • Figure 39. Global Polyglycol Laxatives: by Distribution Channel USD Million (2022-2027)
  • Figure 40. South America Polyglycol Laxatives Share (%), by Country
  • Figure 41. Asia Pacific Polyglycol Laxatives Share (%), by Country
  • Figure 42. Europe Polyglycol Laxatives Share (%), by Country
  • Figure 43. MEA Polyglycol Laxatives Share (%), by Country
  • Figure 44. North America Polyglycol Laxatives Share (%), by Country
  • Figure 45. Global Polyglycol Laxatives: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Boehringer Ingelheim Pharmaceutical (Germany)
  • GSK (United Kingdom)
  • Purdue Pharma (United States)
  • Sucampo Pharmaceuticals (United States)
  • Norgine Limited (United Kingdom)
  • Cipla (India)
  • Perrigo Company (Ireland)
  • Ipsen (France)
Select User Access Type

Key Highlights of Report


May 2022 157 Pages 85 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Polyglycol Laxatives Market Quantitative research analysis
Global Polyglycol Laxatives Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Polyglycol Laxatives market is expected to see a growth of % during projected year 2021 to 2027.
The prominent players of Global Polyglycol Laxatives market are Bayer AG (Germany), Boehringer Ingelheim Pharmaceutical (Germany), GSK (United Kingdom), Purdue Pharma (United States), Sucampo Pharmaceuticals (United States), Norgine Limited (United Kingdom), Cipla (India), Perrigo Company (Ireland) and Ipsen (France), to view complete player list click here

Know More About Global Polyglycol Laxatives Market Report?

Have a Query? Click Here

Other Related Reports

Patulin Analysis Comprehensive Study by Type (Ultraviolet Detection, Kit Detection, Others), End-User (Agriculture, Medical, Chemical, Other), Methods (Liquid Chromatography, Diode Array) Players and...
$ 3500
Muscle Invasive Bladder Cancer Comprehensive Study by Application (Hospital, Research Laboratories, Specialty Clinics), Treatment Type (Neo-Adjuvant Chemotherapy, Post-Operative Chemotherapy), Diagno...
$ 3350
Mercury Poisoning Treatment Comprehensive Study by Type (Methylmercury, Elemental Mercury, Others), Application (Hospital Pharmacy, Online Pharmacy, Retailers, Others), Disease (Acute Mercury Poisoni...
$ 3350
Compounding Chemotherapy Comprehensive Study by Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), Pharmaceutical Dosage Alteration (PDA)), D...
$ 3750
Medicare Advantage Comprehensive Study by Type (Health maintenance organizations (HMO), Preferred Provider Organizations (PPO), Special Need Plans and Private Fee For Service, Medical Savings Account...
$ 3450
Viral Gene Therapy Comprehensive Study by Vector Type (Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus}, Non-Viral Vector {O...
$ 3750